Pilot Study of Pencil Beam Scanning Proton Therapy for Children and Young Adults With Renal Tumors

What this Trial Is About

Researchers are evaluating the use of pencil beam scanning proton therapy PBS-PT in patients with renal tumors, including Wilms tumor and clear cell sarcoma of the kidney CCSK. These tumors are usually treated with surgery, chemotherapy, and radiation, but traditional photon radiation can cause early and late side effects. This pilot study aims to assess whether PBS-PT can reduce acute gastrointestinal toxicity and shorten the duration of radiation therapy while comparing radiation doses to organs at risk with traditional methods. The study involves treating eligible patients with PBS-PT, a form of proton beam radiation characterized by precise dose delivery using the Bragg peak effect, which targets the retroperitoneum more accurately. Patients who require radiation therapy as part of their standard care for Wilms tumor or CCSK may also receive investigational drugs concurrently or within four weeks of starting PBS-PT. This treatment approach is being studied for its safety and feasibility. Participants will be monitored for any non-hematologic toxicities occurring within 90 days after starting proton therapy, using standardized criteria for adverse event grading. Evaluations will include laboratory tests, clinician assessments, and patient-reported quality of life outcomes. The study is sponsored by the Childrens Hospital of Philadelphia, and participation may last through the radiation therapy course and follow-up period to assess acute toxicity and treatment impact.

Pencil Beam Scanning in Patients With Renal Tumors